Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reproductive history of the Danish multiple sclerosis population: A register-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Aggressive multiple sclerosis (1): Towards a definition of the phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Aggressive multiple sclerosis (2): Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Serum neurofilament light as a biomarker in progressive multiple sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Development of treatments for progressive multiple sclerosis (MS) is challenged by the lack of sensitive and treatment-responsive biomarkers of intrathecal inflammation.

OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers.

METHODS: CSF samples from two open-label phase II trials of natalizumab and methylprednisolone in primary and secondary progressive MS. CSF concentrations of 20 inflammatory biomarkers and CSF biomarkers of axonal damage (neurofilament light chain (NFL)) and demyelination were analysed using electrochemiluminescent assay and enzyme-linked immunosorbent assay (ELISA).

RESULTS: In all, 17 natalizumab- and 23 methylprednisolone-treated patients had paired CSF samples. CSF sCD27 displayed superior standardised response means and highly significant decreases during both natalizumab and methylprednisolone treatment; however, post-treatment levels remained above healthy donor reference levels. Correlation analyses of CSF inflammatory biomarkers and NFL before, during and after treatment demonstrated that CSF sCD27 consistently correlates with NFL.

CONCLUSION: These findings validate CSF sCD27 as a responsive and sensitive biomarker of intrathecal inflammation in progressive MS, capturing residual inflammation after treatment. Importantly, CSF sCD27 correlates with NFL, consistent with residual inflammation after anti-inflammatory treatment being associated with axonal damage.

Original languageEnglish
JournalMultiple sclerosis
Volume25
Issue number7
Pages (from-to)937-946
Number of pages10
ISSN1352-4585
DOIs
Publication statusPublished - Jun 2019

    Research areas

  • axonal damage, cerebrospinal fluid, inflammation, methylprednisolone, natalizumab, Primary progressive multiple sclerosis, secondary progressive multiple sclerosis

ID: 58576971